Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct 23;71(7):1790-1794.
doi: 10.1093/cid/ciaa107.

Baloxavir: A Novel Antiviral Agent in the Treatment of Influenza

George M Abraham  1   2 , Jacob B Morton  3 , Louis D Saravolatz  4
Affiliations
Review

Baloxavir: A Novel Antiviral Agent in the Treatment of Influenza

George M Abraham et al. Clin Infect Dis. .

Abstract

Baloxavir marboxil (formerly S-033188) is a prodrug of baloxavir acid (S-033447) and inhibits cap-dependent endonuclease, an essential protein involved in the initiation of viral transcription by cleaving capped mRNA bound to PB2. Its adverse event profile is comparable to oseltamivir but is still vulnerable to resistance. The single-dose baloxavir marboxil is an appealing antiviral regimen for the treatment of influenza among outpatients when compared with longer, twice-daily regimens of oral and inhaled neuraminidase inhibitors. This review focuses on the mode of action, antiviral activity, pharmacokinetics, clinical indications, and safety profiles of this drug. Considerations for formulary addition and its place in therapy are also discussed.

Keywords: baloxavir; influenza; novel antiviral.

PubMed Disclaimer